Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. ACN
10. USO

Go back to Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

Neurocrine Bio. (NBIX) PT Lowered to $150 at Oppenheimer

February 14, 2022 8:30 AM EST

Oppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $150.00 (from $154.00) while maintaining an Outperform rating.

The analyst commented, "NBIX shares have outperformed in 2022 (+7% vs. NBI -14% and S&P 500 -7% YTD) based on a favorable setup that... More